Preclinical Assessment of the Interactions Between the Antiretroviral Drugs, Ritonavir and Efavirenz, and the Tyrosine Kinase Inhibitor Erlotinib

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-015-2856-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor

Prescriber
Pharmacology
2018English

Tyrosine Kinase Inhibitor and Target Therapy

2013English

Structural and Spectroscopic Study of the Tyrosine Kinase Inhibitor PD-153035

Biophysical Journal
Biophysics
2019English

The Fer Tyrosine Kinase Regulates Interactions of Rho GDP-Dissociation Inhibitor a With the Small GTPase Rac

BMC Biochemistry
BiochemistryMolecular Biology
2010English

Pharmacokinetic Interactions Between the Hormonal Emergency Contraception, Levonorgestrel (Plan B), and Efavirenz

Infectious Diseases in Obstetrics and Gynecology
DermatologyGynecologyInfectious DiseasesObstetrics
2012English

Preclinical Overview of Sorafenib, a Multikinase Inhibitor That Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling

Molecular Cancer Therapeutics
Cancer ResearchOncology
2008English

MP470, a Novel Receptor Tyrosine Kinase Inhibitor, in Combination With Erlotinib Inhibits the HER Family/Pi3k/Akt Pathway and Tumor Growth in Prostate Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2009English

‘Covering the Tail’ After Stopping Efavirenz-Based Antiretroviral Therapy

Southern African Journal of HIV Medicine
Infectious Diseases
2020English

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy